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Abstract
OBJECTIVE: To observe the effect of Rupifang Ex-
tract in external use on expression of proto-onco-
genes her2 and tumor suppression genes p16 in rat
breast tissues of mammary hyperplasia model. To
explore the mechanisms of Rupifang Extract in ex-
ternal use for preventing and treating mammary
hyperplasia.
METHODS: Thirty virginal female Wistar rats were
randomized into 5 groups, 6 in each, A: blank con-
trol group; B: model group; C: the low dose group
of Rupifang; D: the middle dose group of Rupifang;
and E: The high dose group of Rupifang. The mam-
mary hyperplasia rat models were produced by in-
jecting estradiol benzoate and progesterone and ir-
ritating by tail nipping. Drug intervention was also
launched during the model formation. After 30
days, the expression of her2 and p16 in breast tis-
sues of rats in each group were detected by the SP
immunohistochemical method.
RESULTS: Compared with Blank control group, the
expression of her2 in breast tissues in Model group
was higher, and the expression of p16 was lower
(P<0.05 or P<0.01). After intervention with Rupi-
fang Extract, compared with Model group, the ex-
pression of her2 in breast tissues in Rupifang
groups was lower, and the expression of p16 higher
(P<0.05 or P<0.01).
CONCLUSION: The mechanisms of Rupifang Ex-
tract in external application for preventing and
treating mammary hyperplasia may be reducing
the expression of proto-oncogenes her2 and in-
creasing the expression of tumor suppression
genes p16.
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INTRODUCTION
Modern medicine considers that the occurrence of
mammary hyperplasia is related to endocrine distur-
bances. So far there is no special drug to treat it. Hor-
mone preparation is commonly used to relieve symp-
toms temporarily. However, its side effects are serious
and the curative effect in long-time using is dubious.
Focal surgical treatment is hardly accepted by patients,
and it is easy to recur.
Traditional Chinese Medicine (TCM) treatment of
mammary hyperplasia has gained quite great progress
in recent years, in which, external therapy is unique
and good in clinical efficacy. Our research group has
obtained a significant effect in the treatment of mam-
mary hyperplasia by Rupifang prescriptions since
2003.
This research was to observe the effect of Rupifang Ex-
tract in external application on the pathomorphology
and expression of her2 and p16 in rat breast tissues of
mammary hyperplasia model, and explore the mecha-
nisms of Rupifang in preventing and treating mamma-
ry hyperplasia.
MATERIALS ANDMETHODS
Animals
Thirty SPF level virginal Wistar rats [weight (200±20)g]
purchased from the Animal Experiment Center of
Southern Medical University, Guangdong Province
(Quality Permit No. SCXK Guangdong 2006-0015).
Reagents and drugs
Rabbit-Anti-Human her2 and Rabbit-Anti-Human
p16 SP immunohistochemical kit (Fuzhou Maixin Bio-
logical Technology Development Co., Ltd.); DAB chro-
mogenic reagents (Beijing Zhongshan Gold Bridge Bio-
technology Co., Ltd.); Estradiol Benzoate Injection:
1ml:1mg (Tianjin Jinyao Amino Acid Co., Ltd.); Pro-
gesterone injection: 1 ml∶20 mg (Tianjin Jinyao Ami-
no Acid Co., Ltd.).
Rupifang: composed of Rose (Flos Rosae Rugosae),
Dingxiang (Flos Caryophylli), Dahuang (Radix et Rhi-
zoma Rhei), Tougucao (Herba Speranskiae Tubercula-
tae), Yanhusuo (Rhizoma Corydalis), Wangbuliuxing
(Semen Vaccariae). The proportion of each herb was 1∶
1. The herbs were decocted for 1 hour, filtrated, and
the decoction was condensed into extract. Each millili-
ter extract (about 2 g) contained about 2 g crude drugs.
Groups and treatment
Thirty rats were randomized into 5 groups, 6 in each.
A. Blank control group; B. Model group; C. The low
dose group of Rupifang; D. The middle dose group of
Rupifang; and E. The high dose group of Rupifang. Af-
ter feeding for 1 week, the rats had regular breast depil-
ation on each pair of breasts by hair-removal cream.
Modeling and drug intervention were started. From
the 2nd day of the experiment to the 30th days, the
rats in group A were injected physical saline (0.5 mL/
kg per day) into the muscle of medial side of hind leg
for 25 day and physical saline (0.2 mL/kg per day) for
5 days. The rats in group B, C, D and E were irritated
by tail nipping 0.5 h/day, 30 days. The rats in group B
were injected Estradiol Benzoate Injection (0.5 mL/kg
per day) into the muscle of medial side of hind leg for
25 days and injected Progesterone (4 mg/kg per day)
for 5 days. The rats in group C were treated in the
same way for modeling as group B, at the same time,
treated with Rupifang Extract (0.2 g) for external appli-
cation in the region of breasts, once a d, and lmin mas-
sage for each breast was given, 30 days. The rats in
group D were treated in the same way for modeling as
group B, at the same time, treated with Rupifang Ex-
tract (0.4 g) for external application in the region of
breasts, once a day, and lmin massage for each breast
was done, 30 days. The rats in group E were treated in
the same way for modeling as group B, at the same
time, treated with Rupifang Extract (0.8 g) for external
application in the region of breasts, once a day, and
lmin massage for each breast was carried out, 30 days.1
All rats were fed whole value grain feedstuff and
tap-water ad libitum. In order to apply Rupifang Ex-
tract more effectively, the rats had breasts depilation by
hair-removal cream regularly.
Specimen collection and index measurement
On the 30th day, the rats were anesthetized with 20%
urethane (1.0 g/kg) through intraperitoneal injection.
The 2nd and 3rd pairs of breasts were removed, fixed
with 10% formaldehyde, and dehydrated by using gra-
dient ethanol, embedded with paraffin, sliced (4 µm),
and stained with HE. Referring to the standard men-
tioned in literature,2 the observation with microscope
on the hyperplasia of breast tissues was performed. Re-
ferring to the judgment standard mentioned in litera-
ture,3,4 the expressions of her2 and p16 in breast tissues
in each group were detected by the SP immunohisto-
chemical method.
Statistical analysis
The experimental data was analyzed by SPSS 11.5. Re-
sults of measurement were expressed by sx ± . Differ-
ences between groups were assessed by one-way ANO-
VA. Paired comparisons were carried out by t-test. Re-
sults of ranked data were analyzed by non-parametric
rank-sum test.
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RESULTS
Effect of Rupifang Extract on histomorphology in rat
breast tissues
There was no hyperplasia in breast tissues in Group A.
Severe hyperplasia in breast tissues was found in Group
B, there was hyperplasia in most lobules, significant ex-
pansion of most acini and ducts, increase of epithelio-
glandular layers, and a large amount of secretion in the
acini and ducts. Moderate and severe hyperplasia was
in Group C. Moderate hyperplasia was in Group D,
there was hyperplasia in most lobules, significant ex-
pansion of some acini and ducts, increase of some epi-
thelioglandular layers, and secretion in the acini and
ducts. There existed the most obvious improvement of
pathomorphological changes in Group E, it's only of
mild and moderate hyperplasia in a few acini, no ex-
pansion of ducts, and a little secretion in some acini
and ducts. (Figure 1). Statistical analysis showed no hy-
perplasia of breast tissues in Group A, compared with
which, the significant difference was presented in
Group B (P<0.01), meaning that exogenous hormone
in combination with emotional stimulus could pro-
duce mammary hyperplasia animal models well. With
the external application of Rupifang Extract, the hyper-
plasia of breast tissues was reduced (P<0.01), and the
middle- and high-dose groups were better in effect
than the low-dose group (P<0.01) (Table 1).
Effect of Rupifang Extract on expression of her2 in
rat breast tissues
The expression of her2 in breast tissues of rats in
Group A was negative. Compared with Group A, the
positive expression of her2 in breast tissues of rats in
Group B was obviously increased (P<0.01 or P<0.05).
The external application of Rupifang Extract made the
expression of her2 in breast tissues in the model groups
significantly reduced (P<0.01), there existed significant
differences among Rupifang groups (P<0.01), the ex-
pression of her2 was lower in the middle- and
high-dose groups than in the low-dose group of Rupi-
fang (P<0.01), and there was no difference between the
middle- and high-dose groups (Table 2, Figure2).
Effect of Rupifang Extract on expression of p16 in
rat breast tissues
Compared with Group A, the positive expression of
p16 in breast tissues in Group B was obviously reduced
(P<0.01). After intervention with Rupifang Extract,
compared with Group B, the positive expression of
p16 in Group C, D, and E was increased. There was
significant difference (P<0.01) between Group D and
B (P<0.01) (Table 3, Figure 3).
DISCUSSION
Rupifang is made of Chinese herbal medicines which
are able to disperse liver stagnation, promote Qi circula-
tion, activate blood, and remove stasis. This prescrip-
tion, made into Chinese herbal plaster,5 is used to treat
mammary hyperplasia of phlegm accumulated with
blood stasis. In the clinical trial, 50 mammary hyper-
plasia patients were treated effectively owing to its func-
tions to improve local blood circulation, restrain hyper-
plasia of mammary gland, promote the absorption of fi-
brous tissues, and relieve pain.
Modern researches demonstrated that the chronic emo-
tional stimulation could cause changes of function of
immune system in rats, thus some cytokines were re-
leased to activate the hypothalamic-pituitary-adreno-
cortica (HPA) axis, then the released corticosterone
(CORT) made the secretion of hypothalamic-pitu-
itary-ovarian (HPO) axis disordered. Consequently, a
series of changes in function of immune system ap-
peared, leading to mammary hyperplasia and breast
cancer eventually.6
Mammary hyperplasia is a hormone dependent dis-
ease, its occurrence is related to out-of-proportion of es-
trogen and progestogen. Estrogen in majority of wom-
an is absolutely or relatively high, while progestogen
low. Estrogen can stimulate the mammary epithelial
and mesenchymal cells to be hyperplastic. Progestogen
can resist estrogen partly and improve the proliferation
of acini. The general method to establish animal mod-
els of the mammary hyperplasia is to use estrogen and
progestogen in combination.7
In this research the mammary hyperplasia animal mod-
els were established by intramuscular injection with ex-
ogenous estradiol and progesterone combined with
emotion stimulus. Histology of breast tissues in each
model group showed severe hyperplasia of breast tis-
sues: hyperplasia of most breast lobules, remarkable ex-
pansion of most acini and ducts, obvious increase of ep-
ithelial layers, and a large amount of secretion in the
acini and ducts. It means that exogenous hormones
(combined with emotion stimulus) can produce the an-
imal model of mammary hyperplasia. After interven-
tion with Rupifang Extract, the hyperplasia of breast
tissues reduced, suggesting that it's effective to relieve
mammary hyperplasia.
Her2 is an oncogene that is most closely related to
breast cancer. It shows her2 gene amplification and
over-expression of its gene product. So her2 antibody
can be used to display on frozen or paraffin sections.
The strong positive expression of her2 can be regarded
as an index to identify early breast cancer. The amplifi-
cation and over-expression of her2 are closely related to
metastasis and recurrence of cancer and survival time
of patient.
Kang's study8 shows that the detection of her2 has a
certain practical reference value on evaluating breast
duct epithelial atypical hyperplasia and its canceration
potential. The research of Cai BY9 suggests that the pos-
itive expression of her2 occurring in atypical hyperpla-
sia period plays an important role in the process from
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mammary hyperplasia to breast cancer.
The decrease or the deletion and inactivation of tumor
suppression gene p16 is closely related to the degree of
mammary hyperplasia and the occurrence and progno-
sis of breast cancer. Along with the severity of breast
duct epithelial atypical hyperplasia, the positive expres-
sion of p16 is getting decreased.10,11
In this research, after the mammary hyperplasia animal
model was established by exogenous hormones (estradi-
ol benzoate and progesterone) combined with tail
pinching, the expression of her2 in breast tissues was
higher and the expression of p16 was lower in the mod-
el group compared with the blank control group (P<
0.05 or P<0.01). Intervention with application of Rupi-
fang Extract makes the expression of her2 in breast tis-
sues reduced significantly (P<0.01) and the expression
of p16 increased. It means that Rupifang can suppress
or reverse the hyperplasia, uncontrolled proliferation,
and malignant transformation of breast epithelium, be-
ing one of mechanisms of Rupifang for preventing and
treating mammary hyperplasia.
Mammary hyperplasia, especially atypical hyperplasia,
is closely related to breast cancer, the incidence of mam-
mary hyperplasia is on the rise nowadays. It is an impor-
tant task to find more convenient and effective drugs
with few side effects and to explore the mechanisms of
these drugs for blocking its development to cancer.
This research is that to establish the mammary hyperpla-
sia animal model by exogenous hormones combined
with tail pinching and apply Rupifang Extract for inter-
vention, and a good effect on the prevention and treat-
ment for mammary hyperplasia animal model is
achieved. Its mechanisms may be that the expression of
proto-oncogene her2 is reduced and the expression of tu-
mor suppression gene p16 increased. This result provides
theoretical basis for clinical application of Rupifang.
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Figure 1 Histomorphological change in rat
breast tissues in each group (HE×200)
A: blank control group; B: model group; C:
the low dose group of Rupifang; D: the
middle dose group of Rupifang; E: the high
dose group of Rupifang.
A B C
D E
Figure 2 her2 expression in rat breast tis-
sues in each group (SP×200)
A: bank control group (-); B: model group
(+); C: the low dose group of Rupifang(+);
D: the middle dose group of Rupifang (+);
E: the high dose group of Rupifang (-).
A B C
D E
Figure 3 p16 expression in rat breast tis-
sues in each group (SP×200)
A: blank control group (+++ ); B: model
group (++); C: the low dose group of Rupi-
fang (+++ ); D: the middle dose group of
Rupifang (+++); E: the high dose group of
Rupifang (+++).
A B C
D E
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